Alder Biopharmaceuticals
Eli Lilly names Ilya Yuffa as executive vice president and president, Lilly Global Markets
Patrik Jonsson, executive vice president and president, Lilly International, will retire at the end of 2026
Novartis presents positive results from two phase 3 trials for relapsing MS
Remibrutinib reduced relapse rates and improved disease progression rates
Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions